Edition:
India

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

4.54USD
17 Nov 2017
Change (% chg)

$0.03 (+0.67%)
Prev Close
$4.51
Open
$4.49
Day's High
$4.66
Day's Low
$4.43
Volume
42,687
Avg. Vol
44,468
52-wk High
$6.59
52-wk Low
$2.81

Summary

Name Age Since Current Position

Steven Rubin

2015 Chairman of the Board

Curtis Lockshin

2015 Chief Executive Officer, Director

Athena Kartsaklis

52 2017 Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller

Shayla Forster

2015 Corporate Secretary

Dmitry Genkin

2015 Director

Kate Inman

2015 Director

Adam Logal

2015 Director

Ran Nussbaum

44 2017 Director

David Rector

68 2015 Additional Independent Director

Biographies

Name Description

Steven Rubin

Curtis Lockshin

Athena Kartsaklis

Ms. Athena Kartsaklis is Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller of the Company. She is a Canadian chartered professional accountant and U.S. certified public accountant and has over 25 years of experience in conducting audits and managing financial reporting and reviewing internal controls. Before joining the Company as corporate controller in May 2017, Ms. Kartsaklis served as a senior vice president of SkyWave Mobile Communications Inc. since December 2013, managing financial reporting, budget and forecast process and audit and other accounting matters. Ms. Kartsaklis was the manager, financial reporting at Alterna Savings, Ottawa, Canada, from September 2012, mainly responsible for financial and administrative reporting. From 1992 to September 2012, Ms. Kartsaklis worked at Deloitte, Hadjipavlou, Sofianos & Cambanis S.A., Athens Greece (Member of Deloitte & Touche International), and became a partner in 2000, overseeing and performing audits and advising clients on audit and accounting matters. Ms. Kartsaklis received a bachelor of commerce degree from Dalhousie University in Halifax, Nova Scotia.

Shayla Forster

Dmitry Genkin

Kate Inman

Adam Logal

Ran Nussbaum

Mr. Ran Nussbaum is Director of the Company. The Pontifax Group is a life sciences venture capital firm with an extensive global portfolio focused on unmet needs within the healthcare industry. Prior to joining Pontifax, Mr. Nussbaum was a partner at Israel's largest business intelligence and strategic consulting firm. Mr. Nussbaum serves, or has served, as a board member on many of Pontifax's portfolio companies, including Kite Pharma, Keros (as chairman), UroGen Ltd, cCam Biotherapeutics (bought by Merck), Eloxx Pharmaceuticals, and NovellusDX.

David Rector

Mr. David S. Rector is Additional Independent Director of Levon Resources Ltd. Mr. Rector has extensive experience in directorship and audit committee roles. Currently, he serves as a director and member of the compensation and audit committee of the Dallas Gold and Silver Exchange Companies Inc. Mr. Rector has been a director of Sevion Therapeutics Inc. ("Sevion") since February 2002, and the interim Chief Executive Officer of Sevion since January 5, 2015. Prior to becoming the interim Chief Executive Officer of Sevion, as an independent director, Mr. Rector served on the audit committee and was the chair of the compensation committee. From January 2014 to January 2015, Mr. Rector was the Chief Operating Officer and a director of MV Portfolios, Inc. Since 1985, Mr. Rector has been the Principal of The David Stephen Group, which provides enterprise consulting services to emerging and developing companies in a variety of industries. Mr. Rector has previously served as an executive officer and a member of the board of directors of numerous other public and private companies. As a result of these professional and other experiences, Mr. Rector has a deep business understanding of developing companies and brings a wealth of corporate governance experience. Mr. Rector received a Bachelor of Science degree in Business/Finance from Murray State University in 1969.